Can Atherosclerosis Actually Be Reversed?

MKP EXPLAINER • OCTOBER 6, 2026

What “reversal” really means

Atherosclerosis develops when cholesterol-rich particles enter artery walls and participate in a long inflammatory process. Treatment does not simply dissolve a blockage like drain cleaner. The major goals are to reduce exposure to atherogenic particles, make plaques less likely to rupture, prevent new plaque formation and, where possible, reduce plaque burden.

Intravascular-ultrasound studies have shown that intensive lipid lowering can halt progression and sometimes produce modest measurable regression. A systematic review and meta-regression published in JAMA Cardiology also found an association between coronary plaque regression and lower rates of major adverse cardiovascular events. The clinically important point is therefore not whether every plaque disappears; it is whether treatment changes the biology and trajectory of disease.

2026: lower LDL, earlier and longer

The 2026 ACC/AHA dyslipidemia guideline replaces the 2018 cholesterol guideline and emphasizes reducing lifetime exposure to plaque-causing lipoproteins. LDL-C goals have returned: for people with established atherosclerotic cardiovascular disease at very high risk, the guideline sets an LDL-C goal below 55 mg/dL. Statins remain foundational therapy, with nonstatin medicines added when appropriate.

Beyond the ordinary cholesterol panel

The new guideline recommends measuring lipoprotein(a), or Lp(a), at least once in adulthood. Lp(a) is largely genetically determined and can identify cardiovascular risk that may not be obvious from LDL-C alone. Apolipoprotein B (ApoB) can also be useful in selected patients because each atherogenic particle carries one ApoB molecule; measuring it can help estimate the number of plaque-forming particles when standard lipid values do not tell the whole story.

The first oral PCSK9 inhibitor

In July 2026, the U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, as an adjunct to diet and exercise for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. Earlier PCSK9 inhibitors were injectable. The approval expands the ways clinicians can lower LDL-C when additional reduction is needed.

What about omega-3 and other supplements?

The cardiovascular evidence is much stronger for established medical therapy than for over-the-counter supplements. The 2026 ACC/AHA dyslipidemia guideline does not recommend dietary supplements as a strategy for managing cholesterol. That does not mean every nutrient is irrelevant; it means a bottle sold for “heart health” should not be assumed to prevent or reverse atherosclerosis.

Omega-3 fatty acids require an important distinction. Ordinary store-bought fish-oil mixtures are not equivalent to prescription therapy. Icosapent ethyl is a purified prescription EPA product with randomized-trial evidence of reducing cardiovascular events in selected statin-treated, high-risk patients with elevated triglycerides. It should not be generalized to every fish-oil supplement or every person taking omega-3s.

Omega-6 fatty acids are essential nutrients and replacing saturated fat with polyunsaturated fats in the diet can be cardioprotective, but that is different from evidence that an omega-6 capsule reverses arterial plaque. Most people obtain omega-6 fatty acids through food.

Other popular products—including antioxidant vitamins, “artery cleanse” formulas and many cholesterol supplements—have not demonstrated the kind of cardiovascular-outcome evidence required to substitute for statins or other guideline-directed therapies. Supplements can also interact with medicines, so individual products and doses belong in a clinician or pharmacist review.

What treatment can—and cannot—promise

Very low LDL-C does not guarantee that an existing plaque will vanish, and imaging evidence of regression should not be confused with a cure. Cardiovascular risk also depends on blood pressure, smoking, diabetes, physical activity, weight, kidney health, genetics and other factors. The strongest evidence supports comprehensive risk reduction rather than chasing a single laboratory number.

← Back to Current Science